Information Provided By:
Fly News Breaks for July 12, 2018
OMER
Jul 12, 2018 | 07:01 EDT
Seaport Global analyst Corey Davis initiated Omeros with a Buy and $30 price target saying Omidria for cataract surgery regains pass-through starting October 1 following new legislation. Davis expects the company to quickly return to an annualized run-rate of $87M, and if it secures permanent reimbursement from CMS, likely $200M-$400M in peak sales.
News For OMER From the Last 2 Days
There are no results for your query OMER